Federal Register

Total Page:16

File Type:pdf, Size:1020Kb

Federal Register FEDERAL REGISTER VOLUME 32 • NUMBER 5 Tuesday, January 10, 1967 • Washington, D.C. Pages 183-246 Agencies in this issue— Advisory Commission on Intergovernmental Relations Army Department Atomic Energy, Commission Civil Aeronautics Board Commodity Credit Corporation Consumer and Marketing Service Federal Aviation Agency Federal Communications Commission Federal Deposit Insurance Corporation Federal Maritime Commission Federal Power Commission, Food and Drug Administration Interior Department Interstate Commerce Commission Land Management Bureau Monetary Offices Navy Department Public Health Service Securities and Exchange Commission Wage and Hour Division Detailed list o f Contents appears inside. S 'Y ear Compilations of Presidential Documents Supplements to Title 3 of the Code of Federal Regulations The Supplements to Title 3 of the Code the President and published in the Federal of Federal Regulations contain the full text Register during the period June 2, 1938- of proclamations, Executive orders, reor­ December 3 1, 1963. Tabular finding aids ganization plans, trade agreement letters, and subject indexes are included. The in­ and certain administrative orders issued by dividual volumes are priced as follows: 1938—1943 Compilation* 1949—1953 Compilation— $7.00 1943—1948 Compilation— $7.00 1954—1958 Compilation— $4.00 1959—1963 Compilation— $6.00 Compiled by Office of the Federal Register, National Archives and Records Service, General Services Administration Order from Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 * Temporarily out of print Published daily, Tuesday through Saturday (no publication on Sundays, Mondays, or on the day after an official Federal holiday), by the Office of the Federal Register, National FEDEMLWREGISTER Archives and Records Service, General Services Administration (mail address National Phone 963-3261 Area Code 202 Archives Building, Washington, D.C. 20408), pursuant to the authority contained in the Federal Register Act, approved July 26, 1935 (49 Stat. 500, as amended; 44 U.S.C., Ch. 8B), under regulations prescribed by the Admin­ istrative Committee of the Federal Register, approved by the President (1 CFR Ch. I). Distribution is made only by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. T h e Federal R egister will be furnished by mail to subscribers, free of postage, for $1.50 per month or $15 per year, payable in advance. The charge for individual copies varies in proportion to the size of the issue (15 cents for the first 80 pages and 5 cents for each additional group of 40 pages, as actually bound). Remit check or money order, made payable to the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. The regulatory material appearing herein is keyed to the Code op F ederal R egulations, which is published, under 50 titles, pur­ suant to section 11 of the Federal Register Act, as amended. The Code op F ederal R egulations is sold by the Superintendent o Documents. Prices of books and pocket supplements are listed In the first F ederal R egister issue of each month. There are no restrictions on the republication of material appearing in the F ederal R egister o r th e Code op Federal R e g u l a t i o n s . Contents ADVISORY COMMISSION ON FEDERAL COM M UNICATIONS INTERSTATE COMMERCE INTERGOVERNMENTAL CO M M ISSIO N CO M M ISSIO N RELATIONS Notices Notices Rules and Regulations Hearings, etc.: Fourth section application for re­ Employee responsibilities and Cosmos Cablevision Corp. and lief ____ _________________________ 245 conduct---------- --------------------- --- 203 Aiken Cablevision, Inc______ 239 Lyrla, Keith H.; statement of changes in financial interests. _ 245 AGRICULTURE DEPARTMENT Stephen Vaughan and Associ­ ates and Multivision North­ See Commodity Credit Corpora­ west, Inc____________ 238 LABOR DEPARTMENT tion; Consumer and Marketing Taxicab radio service__________ 239 See Wage and Hour Division. Service. LAND MANAGEMENT BUREAU ARMY DEPARTMENT FEDERAL DEPOSIT INSURANCE CORPORATION Rules and Regulations Rules and Regulations Public land orders: Medical and dental attendance; Notices Alaska (3 documents)___210, 211, 213 miscellaneous amendments____ 215 Western Maryland Trust Co.; Arizona (2 documents)______ 210, 213 application for exemption_____ 241 Colorado ________________________ 210 ATOMIC ENERGY COMMISSION M o n ta n a __ ._______ •___________ 210 Proposed Rule Making FEDERAL MARITIME New Mexico (5 documents)___ 211, 212,214 Eligibility for access to restricted CO M M ISSIO N Oregon (4 documents) __210, 212-214 data or defense information; South Dakota___________________ 213 use of hallucinogenic drugs for Notices Washington________ 213 nonmedical purposes___________ 234 Approval agreements: W yom ing______________________ 212 Notices American President Lines, Ltd., General Dynamics Corp.; termi­ and China Navigation Co., MONETARY OFFICES nation of facility license_______ 236 Ltd ______________________ !___ 240 Rules and Regulations Isochem, Inc.; order postponing Pacific Coast-Australasian Tar­ hearing----------------------------------- 236 iff Bureau____________________ 240 Conditions for purchase by Treas­ Pacific Westbound Conference. 240 ury of newly-mined domestic CIVIL AERONAUTICS BOARD Trans Pacific Freight Confer­ silver______ . __________________ 195 ence ________________________ 240 Notices NAVY DEPARTMENT Air Transport Assn, et al.; ac­ FEDERAL POWER CO M M ISSIO N Rules and Regulations cessorial cargo services________ 236 International Air Transport Assn. ; Notices Declarations and awards; Viêt- Nam Campaign Medal with de­ fares---------------------------------------- 236 Hearings, etc.: vice________________________ 221 Lake Central Airlines, Inc.; post­ Algonquin Gas Transmission ponement of prehearing con­ C o ------- ------------------------------ 242 PUBLIC HEALTH SERVICE ference_________ ________________ 238 Natural Gas Pipeline Company of America___________________ 243 Rules and Regulations COMMODITY CREDIT Pacific Gas and Electric Co____ 243 Grants to improve quality of train­ CORPORATION Wilson, Alvin, et al_____________ 241 ing centers for allied health Notices professions______________________ 204 FOOD AND DRUG Certificates of interest; sale to SECURITIES AND EXCHANGE financial institutions___________ ADMINISTRATION 235 CO M M ISSIO N Rules and Regulations CONSUMER AND MARKETING Notices Depressant and stimulant drugs; SERVICE exemption of certain combina­ Utah Power & Light Co.; issuance tion “drugs______________________ 197 and sale of short-term notes Rules and Regulations to banks___________ 243 Dates, domestic, produced or Habit-forming drugs; exemption packed in designated part of from prescription dispensing re­ quirements ____________________ 203 TREASURY DEPARTMENT California ; miscellaneous See Monetary Offices. amendments ___________________ 214 HEALTH, EDUCATION, AND WAGE AND HOUR DIVISION defense d e p a r t m e n t WELFARE DEPARTMENT See Army Department; Navy De­ Proposed Rule Making partment. See Food and Drug Administra­ Crediting tips as wages_________ „ 222 tion; Public Health Service. Employee employed in bona fide FEDERAL AVIATION AGENCY capacity of academic admin­ INTERIOR DEPARTMENT istrative personnel or teacher; Rules and Regulations defining and delimiting terms— 228 See also Land Management Bu­ Airborne ATC transponder equip­ reau. Notices ment; TSO-C74a_______ __ i«8 Rules and Régulations Certificates authorizing employ­ ai^craft engines, and pro­ ment of learners at special mini­ pellers; identification__________ 187 Récréation fees_____ _________ ;____ 207 mum rates.._______ ____ _______ 244 185 186 CONTENTS List of CFR Parts Affected (Codification Guide) The following numerical guide is a list of the parts of each title of the Code of Federal Regulations affected by documents published in today's issue. A cumulative list of parts affected, covering the current month to date appears at the end of each issue beginning with the second issue of the month. A cumulative guide is published separately at the end of each month. The guide lists the parts and sections affected by documents published since January 1, 1967, and specifies how they are affected. 3 CFR 21 CFR 43 CFR E x e c u t iv e O r d e r s : 165 ________ 203 18----- -------------—— ---------------- 207 June 13, 1902 (revoked in part by 166 _ 197 P u b l i c L a n d O r d e r s : PLO 4143)__________— _________ 213 686 (revoked in part by PLO July 7, 1910 (revoked in part by 29 CFR 4133) ___________________________ 210 1096 (revoked in part by PLO PLO 4131)______________________ 218 P r o p o s e d R u l e s : June 16, 1911 (revoked in part by i 531______________ 222 4141) __________ 213 PLO 4129)______________________ 210 541_______ ____ 228 2449 (revoked by PLO 4140)______ 213 6143 (revoked in part by PLO 2631 (revoked by PLO 4140)______ 213 4136) _____ _____________________ 211 31 CFR 2749 (revoked in part by PLO 6276 (revoked in part by PLO 4137) ___________________________ 212 195 4136) _____________________ _____ 211 80----------------- ----- 4074 (corrected by PLO 4134)— _ 211 81__________ 195 4129 ___________________________ 210 93_______________ 195 4130 ___________________________ 210 5 CFR 4131 ___________________________ 210 1700— 203 32 CFR > 4132 _____ 210 577______________ 215 4133 ___________________________ 210 733— — . ____ 221 4134 ___________________________ 211 7 CFR 4135 __ _____________ , ____ _ 211 987____' 214 42 CFR 4136 _____________________
Recommended publications
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Federal Register/Vol. 77, No. 115/Thursday, June 14, 2012
    Federal Register / Vol. 77, No. 115 / Thursday, June 14, 2012 / Notices 35691 TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2012, THROUGH MARCH 31, 2012—Continued PMA No., Docket No. Applicant Trade name Approval date P060008.S046, FDA–2012–M–0210 ... Boston Scientific Corp ......................... TAXUS Liberte´ Paclitaxel-Eluting Cor- February 22, 2012. onary Stent System (Monorail and Over-The-Wire Delivery Systems). P030025.S086, FDA–2012–M–0209 ... Boston Scientific Corp ......................... TAXUS Express2 Paclitaxel-Eluting February 22, 2012. Coronary Stent System (Monorail and Over-The-Wire Delivery Sys- tems). P110023, FDA–2012–M–0221 ............ ev3, Inc ................................................ Everflex Self-Expanding Peripheral March 7, 2012. Stent System (Everflex). P070004, FDA–2012–M–0250............ Sientra, Inc.......................................... SIENTRA Silicone Gel Breast Im- March 9, 2012. plants. II. Electronic Access LOCATION: The meeting will be held at submissions. In the process of Persons with access to the Internet the FDA White Oak Campus, 10903 considering these changes, FDA has may obtain the documents at http:// New Hampshire Ave., Bldg. 31 previously made available for comment www.fda.gov/MedicalDevices/ Conference Center, Great Room 1503, versions of documents that support ProductsandMedicalProcedures/ Silver Spring, MD 20993. The following making regulatory submissions in DeviceApprovalsandClearances/ link contains public meeting attendee electronic format using the (eCTD) information as well as frequently asked PMAApprovals/default.htm and http:// specifications. These draft documents questions and answers regarding public www.fda.gov/MedicalDevices/ represented FDA’s major updates to meetings at White Oak: http:// ProductsandMedicalProcedures/ Module 1 of the eCTD based on www.fda.gov/AboutFDA/ DeviceApprovalsandClearances/ previous comments.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al
    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]
  • Cumulative Use of Strong Anticholinergics and Incident Dementia: a Prospective Cohort Study
    Supplementary Online Content Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. Published online January 26, 2015. doi:10.1001/jamainternmed.2014.7663. eTable 1. List of Anticholinergics and Minimum Effective Daily Dose eTable 2. Risk for Incident Dementia and Alzheimer Disease With 10-Year Cumulative Anticholinergic Use According to Subtype eTable 3. Risk for Incident Dementia and Alzheimer Disease With 10-Year Cumulative Anticholinergic Use Adjusted for Recent Depressive Symptoms eTable 4. Risk for Incident Dementia and Alzheimer Disease With 9-Year Cumulative Anticholinergic Use With 2-Year Lag Time eTable 5. Risk for Incident Dementia and Alzheimer Disease Dividing Heavy Anticholinergic Use Into Past, Recent, and Continuous eFigure 1. Example Calculation of Total Standardized Daily Dose eFigure 2. Scheme for Exposure Definition for Primary and Exploratory Analysis This supplementary material has been provided by the authors to give readers additional information about their work. © 2015 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/30/2021 eTable 1. List of anticholinergics and minimum effective daily dosea Antihistamines Antiparkinson agents Gastrointestinal antispasmodics b Azatadine (2 mg) Benztropine (0.5 mg) Adiphenine Bromodiphenhydramine Biperiden Alverine Brompheniramine (12 mg) Chlorphenoxamine Anisotropine Carbinoxamine Cycrimine Atropine products (0.0582 Chlorpheniramine
    [Show full text]
  • A Computational Tool for Pathway-Based Rational Drug Repositioning Supplementary Information
    gene2drug: a Computational Tool for Pathway-based Rational Drug Repositioning Supplementary Information Francesco Napolitano1, Diego Carrella1, Barbara Mandriani1, Sandra Pisonero1, Diego Medina1, Nicola Brunetti-Pierri1,2, and Diego di Bernardo1,3 1Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli (NA), 80078, Italy. 2Department of Translational Medicine, Federico II University, 80131 Naples, Italy 3Department of Chemical, Materials and Industrial Production Engineering, University of Naples Federico II, 80125 Naples, Italy. List of Figures S1 Relation between PPI network-based and pathway based approaches. Given a therapeutic gene and the set of pathways it is annotated to according to the different databases, the other genes in the same pathways are topologically closer to it in the PPI network as compared to randomly chosen genes. The average shortest path from the selected gene to other pathway members is reported on the y axis for each database. 3 S2 Size of intersection between existent evidence scores in the STITCH database (subset matched against the Cmap database) as a percentage of the total number of evidences. Numbers on the diagonal represent how many times a drug-target evidence exists divided by the total number of reported pairs. A \combined score" always exist if one of the other evidences exist, thus \combined score" covers 100% of the pairs. Conversely, an \experimental" score is only present for 14% of the pairs. The \Text mining" evidence strongly drives the \combined score" covering 61% of all the known protein-target interactions in STITCH. 4 S3 Relative luminescence units (RLU) in Hepa1-6 cells transfected with a plasmid ex- pressing the luciferase gene under the control of the GPT promoter and incubated with various concentrations of fulvestrant.
    [Show full text]
  • Association of Cardiovascular Risk with Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: a Nested Case-Control Study
    Supplementary Online Content Wang M-T, Liou J-T, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. Published online January 2, 2018. doi: 10.1001/jamainternmed.2017.7720 eMethods 1. Development of a disease risk score-matched nested case-control study eMethods 2. Modeling a nonlinear duration-response association using a restricted cubic splines function model. eMethods 3. A case-crossover study for assessing the association between the CVD risk and use of LABAs and LAMAs eTable 1. Diagnosis codes used to define the comorbidities and individual drugs of comedications eTable 2. Comparison of CVD risk between new LAMA use and new LABA use eTable 3. Risk of each primary cardiovascular outcome with new LABA and LAMA use eTable 4. Case-crossover analysis for the risk of CVDs with use of LABA and LAMA within 30 days eTable 5. Clinical characteristics of CVD patients during the case and control periods in an alternative case-crossover study eTable 6. Numbers needed to harm for patients who had an increased CVD risk from using LABAs and LAMAs in our primary and secondary analyses eFigure 1. Overview for the adopted nested case-control study design. CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; ER, emergency room; NHI represents National Health Insurance eFigure 2. Specification of case and control periods in an alternative case-crossover study eFigure 3. The impact of unmeasured confounders assessed by the rule-out method eFigure 4. Study flow diagram outlining the selection of study cohort © 2018 American Medical Association.
    [Show full text]